178 related articles for article (PubMed ID: 28511180)
1. Response Predictors of S-1, Cisplatin, and Docetaxel Combination Chemotherapy for Metastatic Gastric Cancer: Microarray Analysis of Whole Human Genes.
Kitamura S; Tanahashi T; Aoyagi E; Nakagawa T; Okamoto K; Kimura T; Miyamoto H; Mitsui Y; Rokutan K; Muguruma N; Takayama T
Oncology; 2017; 93(2):127-135. PubMed ID: 28511180
[TBL] [Abstract][Full Text] [Related]
2. Feasibility and efficacy of preoperative chemotherapy with docetaxel, cisplatin and S-1 in gastric cancer patients with para-aortic lymph node metastases.
Fushida S; Fujimura T; Oyama K; Yagi Y; Kinoshita J; Ohta T
Anticancer Drugs; 2009 Sep; 20(8):752-6. PubMed ID: 19543076
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
Sato Y; Takayama T; Sagawa T; Takahashi Y; Ohnuma H; Okubo S; Shintani N; Tanaka S; Kida M; Sato Y; Ohta H; Miyanishi K; Sato T; Takimoto R; Kobune M; Yamaguchi K; Hirata K; Niitsu Y; Kato J
Cancer Chemother Pharmacol; 2010 Sep; 66(4):721-8. PubMed ID: 20041328
[TBL] [Abstract][Full Text] [Related]
4. [Combination chemotherapy using docetaxel, cisplatin, and S-1 for far advanced gastric cancer].
Hamakawa T; Kurokawa Y; Takiguchi S; Takahashi T; Yamasaki M; Miyata H; Nakajima K; Mori M; Dok Y
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2342-4. PubMed ID: 22202376
[TBL] [Abstract][Full Text] [Related]
5. Potential of extravasated platelet aggregation as a surrogate marker for overall survival in patients with advanced gastric cancer treated with preoperative docetaxel, cisplatin and S-1: a retrospective observational study.
Saito H; Fushida S; Miyashita T; Oyama K; Yamaguchi T; Tsukada T; Kinoshita J; Tajima H; Ninomiya I; Ohta T
BMC Cancer; 2017 Apr; 17(1):294. PubMed ID: 28449652
[TBL] [Abstract][Full Text] [Related]
6. Conversion therapy for inoperable advanced gastric cancer patients by docetaxel, cisplatin, and S-1 (DCS) chemotherapy: a multi-institutional retrospective study.
Sato Y; Ohnuma H; Nobuoka T; Hirakawa M; Sagawa T; Fujikawa K; Takahashi Y; Shinya M; Katsuki S; Takahashi M; Maeda M; Okagawa Y; Naoki U; Kikuch S; Okamoto K; Miyamoto H; Shimada M; Takemasa I; Kato J; Takayama T
Gastric Cancer; 2017 May; 20(3):517-526. PubMed ID: 27553665
[TBL] [Abstract][Full Text] [Related]
7. A phase II study of neoadjuvant combination chemotherapy with docetaxel, cisplatin, and S-1 for locally advanced resectable gastric cancer: nucleotide excision repair (NER) as potential chemoresistance marker.
Hirakawa M; Sato Y; Ohnuma H; Takayama T; Sagawa T; Nobuoka T; Harada K; Miyamoto H; Sato Y; Takahashi Y; Katsuki S; Hirayama M; Takahashi M; Ono M; Maeda M; Takada K; Hayashi T; Sato T; Miyanishi K; Takimoto R; Kobune M; Hirata K; Kato J
Cancer Chemother Pharmacol; 2013 Mar; 71(3):789-97. PubMed ID: 23338051
[TBL] [Abstract][Full Text] [Related]
8. [A case of cervical lymph node recurrence of advanced gastric cancer responding to combination therapy of S-1, CDDP and docetaxel].
Sugishita H; Ishida N; Yoshida M; Sato K; Doi T; Horiuchi A; Watanabe Y
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1385-8. PubMed ID: 20647733
[TBL] [Abstract][Full Text] [Related]
9. Validity of neoadjuvant chemotherapy with docetaxel, cisplatin, and S-1 for resectable locally advanced gastric cancer.
Sasaki K; Onodera S; Otsuka K; Satomura H; Kurayama E; Kubo T; Takahashi M; Ito J; Nakajima M; Yamaguchi S; Miyachi K; Kato H
Med Oncol; 2017 Aug; 34(8):139. PubMed ID: 28707042
[TBL] [Abstract][Full Text] [Related]
10. [A case report-highly advanced gastric cancer leading to perforation during neoadjuvant chemotherapy with docetaxel, cisplatin and S-1].
Mihara K; Egawa T; Kemmochi T; Irino T; Okamura A; Inaba Y; Eto E; Segami K; Ito Y; Hayashi S; Nagashima A
Gan To Kagaku Ryoho; 2011 Nov; 38(12):2357-9. PubMed ID: 22202381
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of taxane monotherapy in advanced gastric cancer refractory to triplet chemotherapy with docetaxel, cisplatin, and S-1: a multicenter retrospective study.
Iizumi S; Takashima A; Narita Y; Tajika M; Muro K; Kawai S; Yasui H; Matsushima T; Takahari D; Nagashima K; Boku N
Cancer Chemother Pharmacol; 2017 Sep; 80(3):575-582. PubMed ID: 28730292
[TBL] [Abstract][Full Text] [Related]
12. Impacts of fluorouracil-metabolizing enzymes on the outcomes of patients treated with S-1 alone or S-1 plus cisplatin for first-line treatment of advanced gastric cancer.
Koizumi W; Tanabe S; Azuma M; Ishido K; Nishimura K; Sasaki T; Nakatani K; Higuchi K; Nakayama N; Katada C
Int J Cancer; 2010 Jan; 126(1):162-70. PubMed ID: 19588501
[TBL] [Abstract][Full Text] [Related]
13. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial.
Koizumi W; Narahara H; Hara T; Takagane A; Akiya T; Takagi M; Miyashita K; Nishizaki T; Kobayashi O; Takiyama W; Toh Y; Nagaie T; Takagi S; Yamamura Y; Yanaoka K; Orita H; Takeuchi M
Lancet Oncol; 2008 Mar; 9(3):215-21. PubMed ID: 18282805
[TBL] [Abstract][Full Text] [Related]
14. Conversion surgery after combination chemotherapy of docetaxel, cisplatin and S-1 (DCS) for far-advanced gastric cancer.
Mieno H; Yamashita K; Hosoda K; Moriya H; Higuchi K; Azuma M; Komori S; Yoshida T; Tanabe S; Koizumi W; Katada N; Watanabe M
Surg Today; 2017 Oct; 47(10):1249-1258. PubMed ID: 28365892
[TBL] [Abstract][Full Text] [Related]
15. Combination of low-dose docetaxel and standard-dose S-1 for the treatment of advanced gastric cancer: efficacy, toxicity, and potential predictive factor.
Cui Y; Li Q; Yu Y; Chen Y; Feng Y; Wang Y; Liu T
Cancer Chemother Pharmacol; 2013 Jan; 71(1):145-52. PubMed ID: 23064955
[TBL] [Abstract][Full Text] [Related]
16. [Efficacy and safety of S-1 plus docetaxel combination therapy for patients with advanced gastric cancer].
Nishiwaki H; Yamada T; Tachi K; Iwasaki H; Hori Y; Umemura S; Yamakawa Y; Kurimoto T; Ban T; Fujiwara K; Hayashi K; Nemoto A; Shiroko J; Orito E
Gan To Kagaku Ryoho; 2009 Oct; 36(10):1663-6. PubMed ID: 19838024
[TBL] [Abstract][Full Text] [Related]
17. A randomized phase 2 study of docetaxel and S-1 versus docetaxel and cisplatin in advanced gastric cancer with an evaluation of SPARC expression for personalized therapy.
Jeung HC; Rha SY; Im CK; Shin SJ; Ahn JB; Yang WI; Roh JK; Noh SH; Chung HC
Cancer; 2011 May; 117(10):2050-7. PubMed ID: 21523716
[TBL] [Abstract][Full Text] [Related]
18. BAK is a predictive and prognostic biomarker for the therapeutic effect of docetaxel treatment in patients with advanced gastric cancer.
Kubo T; Kawano Y; Himuro N; Sugita S; Sato Y; Ishikawa K; Takada K; Murase K; Miyanishi K; Sato T; Takimoto R; Kobune M; Nobuoka T; Hirata K; Takayama T; Mori M; Hasegawa T; Kato J
Gastric Cancer; 2016 Jul; 19(3):827-38. PubMed ID: 26486506
[TBL] [Abstract][Full Text] [Related]
19. Chemo-resistant Gastric Cancer Associated Gene Expression Signature: Bioinformatics Analysis Based on Gene Expression Omnibus.
Liu JB; Jian T; Yue C; Chen D; Chen W; Bao TT; Liu HX; Cao Y; Li WB; Yang Z; Hoffman RM; Yu C
Anticancer Res; 2019 Apr; 39(4):1689-1698. PubMed ID: 30952707
[TBL] [Abstract][Full Text] [Related]
20. [A case of S-1/CDDP chemotherapy for inoperable advanced gastric cancer which led to gastrectomy with histological complete response].
Kobayashi K; Tanizaki K; Aoki T; Takachi K; Nishioka K; Matsumoto T; Komori T; Chono T; Kato A; Hyuga S; Watanabe R; Uemura Y
Gan To Kagaku Ryoho; 2011 Nov; 38(12):1951-3. PubMed ID: 22202249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
